This pilot study will i) evaluate the efficacy and the safety of bendamustine-based
combination chemotherapy and ii) investigate the pharmacokinetics (PK)of bendamustine in
plasma and CSF when given as salvage treatment for patients with relapsed or refractory
primary central nervous system lymphoma (PCNSL).